Digoxin Versus Ivabradine in Heart Failure With Reduced Ejection Fraction
NCT ID: NCT02046044
Last Updated: 2014-01-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE4
60 participants
INTERVENTIONAL
2014-01-31
2014-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Digoxin & Ivabradine to Treat Heart Failure
NCT01699776
Digoxin Versus Ivabradine in Heart Failure With Preserved Systolic Function
NCT01796093
Digoxin Short Term Treatment Assessment Randomized Trial in AHF
NCT02544815
Efficacy of Ivabradine in Patient With Both Persistent Atrial Fibrillation and Heart Failure With Reduce Ejection Fraction
NCT04308031
Effect of Dapagliflozin on VT in Patients With Heart Failure.
NCT05550441
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ivabradine
Ivabradine: initial dose of 5 mg b.id. dose up-titration to 7,5 mg b.id. in 2 weeks due to the heart rate and maintaining the last dose during 6 months.
Ivabradine
Digoxin
Digoxin: Digoxin 0,25 mg once a day 5 days per week during 6 months.
Digoxin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Digoxin
Ivabradine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Sinus rhythm with heart rate of 70 beats per minute or higher
* Symptomatic heart failure with functional capacity of New York Heart Association class II, III, IV
Exclusion Criteria
* Atrial fibrillation
* Pace maker rhythm
* Advanced stage chronic obstructive lung disease
* Comorbidity with expected survival below 1 year
18 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kocaeli University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kurtulus Karauzum
Kurtulus Karauzum
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kurtulus Karauzum, MD
Role: PRINCIPAL_INVESTIGATOR
Kocaeli University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kocaeli University
Kocaeli, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KK&DU-Iva-Dig2014
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.